Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND
December 06, 2024 17:30 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and...
Tandy Leather Factory Announces Agreement to Sell Headquarters Facilities
December 06, 2024 17:15 ET
|
Tandy Leather Factory, Inc.
FORT WORTH, Texas, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Tandy Leather Factory, Inc. (the “Company”, Nasdaq: TLF) today announced that it had signed a Purchase and Sale Agreement to sell its corporate...
Zevra Therapeutics Announces Organizational Changes
December 06, 2024 17:00 ET
|
Zevra Therapeutics
CELEBRATION, Fla., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment...
Globalink Investment Inc. Announces Charter and Trust Agreement Amendments
December 06, 2024 17:00 ET
|
Globalink Investment Inc.
New York, NY, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Globalink Investment Inc. (Nasdaq: GLLI, GLLIW, GLLIR, GLLIU) (“Globalink” or the “Company”), a special purpose acquisition company, announced today...
BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity
December 06, 2024 16:35 ET
|
BioAge Labs, Inc.
Decision follows observations of liver transaminitis without clinically significant symptoms in some subjects on azelaprag Company will evaluate data from patients enrolled to date and share updated...
M3 Group Joins MEDIROM Mother Labs’ Series A Financing Round at JPY9 Billion (as of December 1, 2024, approximately USD $59,000,000) Pre-Money Valuation
December 06, 2024 16:30 ET
|
MEDIROM Healthcare Technologies Inc.
TOKYO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“MEDIROM”) announces that M3, Inc. (TOKYO PRIME: 2413), or an affiliate within the M3 group, is...
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 06, 2024 16:30 ET
|
Tempest Therapeutics
BRISBANE, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated...
Cerence AI Announces Equity Grant to Employee Under Inducement Plan Pursuant to Nasdaq Listing Rule 5635(c)(4)
December 06, 2024 16:30 ET
|
Cerence Operating Company
BURLINGTON, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Cerence Inc. (NASDAQ: CRNC) (“Cerence AI”), a global industry leader in AI for transportation, today announced that, in connection with Antonio...
IREN closes $440 million convertible notes offering
December 06, 2024 16:21 ET
|
IREN
SYDNEY, Dec. 06, 2024 (GLOBE NEWSWIRE) -- IREN Limited (NASDAQ: IREN) (ACN 629 842 799) (“IREN”) today announced the closing of its offering of $440 million aggregate principal amount of 3.25%...
Presidio Granted Second 180-Day Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule
December 06, 2024 16:15 ET
|
Presidio Property Trust, Inc.
Presidio Granted Second 180-Day Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule